Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPL 344

Next Previous
Drug Profile

IPL 344

Alternative Names: IPL-344

Latest Information Update: 16 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Weizmann Institute of Science
  • Developer Immunity Pharma
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase modulators; Apoptosis inhibitors; Proto-oncogene protein c-akt modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Amyotrophic lateral sclerosis

Most Recent Events

  • 07 Apr 2025 Efficacy , adverse event and pharmacokinetics data from a phase I/IIa trial in Amyotrophic lateral sclerosis released by Immunity Pharma
  • 17 Jan 2024 Efficacy, adverse events and pharmacodynamic data from a phase IIa trial in Amyotrophic lateral sclerosis released by Immunity Pharma
  • 17 Jan 2024 Immunity Pharma plans a pivotal trial for Amyotrophic lateral sclerosis

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top